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Abstract
Introduction—Achieving successful tissue regeneration following traditional therapeutic
protocols, combining bone grafts and barrier membranes, may be challenging in certain clinical
scenarios. A deeper understanding of periodontal and peri-implant wound healing and recent
advances in the field of tissue engineering have enabled clinicians with novel means to obtain
predictable clinical outcomes. The use of growth factors such as recombinant human platelet-
derived growth factor-BB (rhPDGF) with biocompatible matrices to promote tissue regeneration
represents a promising approach in the disciplines of periodontology and implantology.
Areas covered—This review covers the basic principles of bone and periodontal regeneration,
and provides overview of the biology of PDGF and its potential to predictably and reproducibly
promote bone regeneration in regular clinical practice. The results of preclinical and clinical
human studies evaluating the effectiveness of growth factor-enhanced matrices are analyzed and
discussed.
Expert opinion—Current available evidence supports the use of rhPDGF-enhanced matrices to
promote periodontal and peri-implant bone regeneration.
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A. INTRODUCTION
Clinicians are frequently faced with the challenge of treating patients with significant
alveolar bone loss due to periodontal disease, congenital abnormalities, tumors, traumatic
injury, or resorption secondary to tooth loss. Conventional treatment procedures may be
ineffective in achieving bone regeneration, leaving both the clinician and the patient
dissatisfied with the outcome. Growth factors (GFs) have long been believed to have the
potential to accelerate the healing process and, therefore, enhance tissue regeneration in
challenging clinical scenarios.
GFs are natural biological mediators that regulate key cellular events that are part of the
process of tissue repair and regeneration. After binding of GFs to specific cell membrane
receptors of target cells, intracellular signaling pathways are induced, which typically results
in the activation of genes that may ultimately change cellular activity and phenotype.
However, the effect of each GF is regulated through a complex system of feedback loops,
which involve other GFs, enzymes, and binding proteins. Recent advances in the areas of
cellular and molecular biology allowed better understanding of the functions of GFs and
their participation in the different phases of wound healing. In vitro and in vivo studies have
confirmed that GFs can enhance the capacity of tissues to regenerate by regulating cell
chemoattraction, differentiation and proliferation.1, 2
One of the most extensively studied GFs is platelet-derived growth factor (PDGF). This
growth factor has been well characterized and has broad wound healing activities in both
hard (bone) and soft (skin, gingival) tissue. Recently, a combination of purified recombinant
human PDGF (rhPDGF) with synthetic ceramic matrices (beta-tricalcium phosphate [β-
TCP]) has been proposed as a periodontal regenerative agent. The efficacy of growth factor-
enhanced matrices in periodontal therapies has been rigorously examined in a variety of
preclinical animal models and long-term human clinical studies. The results of these studies
will be discussed in this review, along with the potential for PDGF-enhanced matrices to
predictably and reproducibly promote bone regeneration in clinical practice.
B. OSSEOUS REGENERATION
B.1. Bone Grafting
A variety of biologic and synthetic materials to augment existing bone and enhance bone
regeneration are available to clinical practitioners. Autogenous bone grafting has been
traditionally considered the gold standard for treating bone defects or deficiencies. The
clinical benefits derived from the use of autogenous bone grafts are primarily due to 1) the
presence of osteoblasts and osteoprogenitor cells within the graft; 2) release of naturally
occurring GFs and other biochemical mediators; and 3) the osteoconductive nature of the
substrate itself. Autogenous grafts may be obtained from intraoral sites such as the
mandibular symphysis or the ascending ramus, or may be harvested from extraoral sites
such as the iliac crest or the proximal tibia.3 However, the use of autogenous bone grafts
may also involve a series of disadvantages, such as limited availability and increased
morbidity associated with a second surgical site.
When autogenous bone is not readily available, alternative bone sources can be utilized.
Tissue matrices, including allogenic, xenogenic and synthetic graft materials are available
for use. These bone substitutes function primarily by passively guiding or “conducting” cell
migration through the matrix, eventually leading to repair of the defect. These materials may
be used alone, in combination with autogenous grafts or in combination with titanium
meshes, barrier membranes, or other passive materials designed to act as a physical guide or
cell-occlusive element.4 While these options are useful for maintaining space and a
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framework for tissue deposition during the process of bone regeneration, results obtained
with passive therapeutic matrices have been variable, depending upon their inherent physical
and chemical properties as well as the patient’s individual healing response.5, 6
B.2. Tissue Engineering Approaches for Bone Regeneration
Novel tissue engineering techniques have been recently developed to regenerate bone in
challenging defect sites, where spontaneous repair is not achievable.7 On a fundamental
level, bone tissue engineering involves supplying four basic elements required for bone
formation to the defect site: adequate blood supply, bone forming cells, scaffolds or
matrices, and signaling molecules, such as GFs (Figure 1). Osteoblasts or bone precursor
cells may be provided by direct scaffold seeding (in vitro tissue engineering) or they may be
induced by biochemical mediators to migrate into the scaffold from the marginal host bone
(in vivo tissue engineering). Scaffolds provide a foundation to support cell attachment and
proliferation in the defect site, and facilitate blood clot stabilization, which additionally
prevents tissue collapse, all essential events in the initial stages of healing regenerative
processes.8 Some scaffold materials used in bone regeneration are collagen, autogenous or
allograft bone, resorbable polymers and porous calcium phosphate ceramics. GFs serve to
stimulate native cell migration into the defect site and increase proliferation of these cells to
populate the scaffold through specific chemotactic and mitogenic signals. Different scaffold
materials (naturally-derived and synthetic) are available which are biocompatible with GFs
and through their use, enable the delivery of GFs to different sites. With newer
bioengineered materials, GFs can be incorporated directly into the scaffold and their release
from these materials controlled over a predetermined period of time.9 This mechanism of
action contrasts with bone morphogenetic proteins (BMPs), which primarily exert their
effect through osteoinduction (stimulating differentiation of mesenchymal cells into bone
forming cells).10, 11
C. PDGF FOR BONE REGENERATION IN PERIODONTAL AND PERI-
IMPLANT SITES
GFs and BMPs have been the focus of considerable attention in recent years by dental and
orthopedic researchers.12, 13 These biological molecules offer the possibility of using
biomaterials that are readily available for the clinician to attempt bone regeneration in a
controlled, predictable manner. While a considerable number of bone GFs and morphogens
have been identified, one of the most extensively characterized growth factors for clinical
applications is PDGF.
In the late 1980’s, Lynch and co-workers first discovered in an animal study that PDGF
promotes regeneration of periodontal tissues including bone, cementum and periodontal
ligament.14 Since then, numerous studies have been published providing a deeper
understanding of the mechanism of action and therapeutic potential of this molecular
mediator. PDGF is a naturally occurring protein that is found abundantly in the bone matrix
in at least three different forms: PDGF-AA, PDGF-AB and PDGF-BB.15 This GF is locally
released by blood platelets during clotting following soft or hard tissue injury.16 Once it is
released from the platelets, PDGF binds to specific cell surface receptors promoting rapid
cell migration (chemotaxis), and proliferation (mitogenesis), in the area of injury.17 In vitro
and in vivo studies have demonstrated that PDGF is a potent chemotactic and mitogenic
factor for gingival and periodontal ligament fibroblasts, cementoblasts and osteoblasts.14,
18–20
While growth factor proteins have been shown to be potent stimulators of wound repair, the
ability to utilize concentrated forms of these proteins contained within blood platelets for
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routine oral surgical treatment was not introduced until 1998, when Marx and co-workers
proposed the use of autologous platelet concentrates.21 The preparation of platelet
concentrates consists of isolating the platelets naturally present in whole autologous blood
by a selective process of centrifugation, and subsequently activating them to release their
growth factor content, including super-physiologic concentrations of PDGF, TGF-β and
IGF-I, among others.22 These factors are directly applied to the treatment site in order to
promote tissue regeneration or repair. Thrombin/calcium preparations initiate clotting,
including the conversion of fibrinogen to fibrin, resulting in a clinically useful platelet rich
plasma (PRP) gel that can additionally improve the handling and efficacy of particulate
autografts and bone substitutes. A variety of protocols to produce platelet concentrates have
been described to date. However, studies evaluating the effect of platelet gel concentrates
alone, or in combination with osteoconductive matrices, on graft maturity, bone density, and
new bone formation in a number of different clinical applications have demonstrated
somewhat variable outcomes ranging from excellent results in some studies to no apparent
benefit in others.23 The differences in outcomes are thought to be a result in variability in
platelet concentration as well as individual patient healing responses. In summary, platelet
concentrates provide good handling characteristics alone or in combination with a variety of
matrices, however with the primary disadvantage of the technique being the need to obtain
blood from the patient and lack of a predictable response following treatment according to
current evidence.23
To overcome some of these limitations other therapeutic approaches have been developed.
Advances in recombinant technology have lead to the synthesis of proteins in a controlled
manner, which in turn enables production of concentrated and purified molecules in large
quantities. This has led to the development and commercialization of recombinant growth
factor/matrix combination products. Combination products represent an emerging new trend
in regenerative therapeutics and have gained increasing attention as a strategy to optimize
tissue regeneration. These products synergize tissue specific matrices with highly
concentrated bioactive proteins to actively recruit progenitor cells for the treatment of tissue
deficiencies. The ability to combine highly concentrated forms of signaling proteins with
scaffolds has enabled clinical researchers to develop improved regenerative products taking
advantage of the physical and chemical characteristics required for specific cell attachment,
growth and differentiation.
Recombinant human platelet-derived growth factor (rh-PDGF) was the first recombinant
protein to be approved by the US Food and Drug Administration for treatment of chronic
foot ulcers in diabetic patients (Regranex, Ethicon Inc. Somerville, NJ).24, 25 Widespread
use in this application has established the safety and effectiveness of PDGF for soft tissue
regeneration.26 Additionally, rhPDGF for bone regeneration has been rigorously tested in
preclinical studies, which indicate that PDGF has the potential to be used to direct and
control bone regeneration in humans. For example, a tibial osteotomy study using PDGF in
rabbits demonstrated that this protein substantially increased the rate of fracture repair as
compared to untreated control sites.27 In addition, the biomechanical strength of the repair
tissue in rhPDGF treated animals was not significantly different from un-operated normal
intact bone. Furthermore, when PDGF was injected subperiosteally in long bones, it induced
intramembranous bone formation.28 In a detailed study in osteoporotic animals involving
dual-energy x-ray absorptiometry (DEXA) bone density scans, quantitative computed
tomography scans, biomechanical testing and histological analyses, periodic systemic
injection of rhPDGF substantially increased bone density in the long bones and in the spine.
29
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C.1. Preclinical Studies Using PDGF for Periodontal and Peri-implant Regeneration
In order to evaluate the potential and safety of this therapy, extensive in vivo preclincal
studies have been performed using PDGF alone or in combination with other GFs such as
insulin-like growth factor (IGF) to treat periodontal and peri-implant defects. In a previously
mentioned study, Lynch and co-workers first published evidence of the regenerative
potential of PDGF-BB when used to treat naturally occurring periodontal defects in dogs.14
Most notably, this study showed increased cellular activity after treatment with PDGF-BB,
leading to increased bone, cementum and periodontal ligament regeneration. In the related
study examining its use around dental implants, direct application of an rhPDGF/IGF
mixture into implant sites in dogs produced a two to three times increase in the number of
peri-implant spaces filled with bone at early time points.30 Promising results were also seen
in immediate extraction socket implants treated with polytetrafluoroethylene (PTFE)
membranes and PDGF/IGF. Bone density and bone-to-implant contact were increased
twofold for the growth factor treated sites, as compared to the membrane alone or
membranes combined with bone grafts.31 These early studies were instrumental in
establishing preclinical evidence for the potential of PDGF treatment in not only
periodontal, but also peri-implant sites.
The adjunctive effect of rhPDGF therapy for implant site development indications has also
been investigated in animal models. Simion and co-workers conducted an animal study to
investigate the outcomes of vertical bone augmentation following the application of
rhPDGF-BB.32 Bilateral severe bone defects were surgically created in the mandibles
foxhound dogs and three months later, each of the defects was treated following one of these
three augmentation protocols: 1. Anorganic bovine bone blocks covered with a collagen
membrane, 2. Anorganic bovine bone blocks infused with rhPDGF-BB, or 3. Anorganic
bovine bone blocks infused with rhPDGF-BB covered with a collagen membrane. In all
cases, anorganic bovine bone blocks were secured using two titanium dental implants. At
four months the results were more favorable for the group that included the blocks with
rhPDGF-BB, illustrating the importance of the periosteal blood supply in the outcomes of
GF therapy. This study demonstrated that the rhPDGF-BB infused matrix significantly
enhanced bone formation and gingival healing in large, critical size alveolar bone defects.
Radiographic and histological analysis indicated that the greatest bone regeneration occurred
for the rhPDGF-BB infused graft block without the collagen membrane (Figure 2). Unlike
traditional guided bone regeneration procedures, the membrane appeared to block the
migration of bone forming cells into the scaffold. Histological analysis indicated that bone
formation occurred from both the coronal and apical surfaces of the rhPDGF-BB treated
graft, suggesting that osteoblasts and other bone-forming precursor cells were recruited into
the graft from both the superior (coronal, periosteal surface) and the inferior (apical, marrow
spaces) boundaries. Additionally, bone growth appeared more robust from the periosteal
surface when compared to the bone formation observed at the original osseous crest.
According to these results, rhPDGF-BB may have exerted a potent chemotactic effect on
osteogenic cells present in the periostium, when a barrier membrane was not placed.
In addition to applications of PDGF in vertical ridge augmentation procedures, preclinical
studies by Schwarz and coworkers recently evaluated early healing outcomes following
horizontal ridge augmentation.33 Bilateral mandibular surgically created defects were treated
with either beta-tricalcium phosphate (β−TCP) covered with a collagen membrane (CM) or
a combination of β−TCP and CM plus rhPDGF-BB, following a split-mouth design. The
results of this study revealed that the group containing rhPDGF-BB showed better results in
terms of mineralized tissue and total augmented area at 3 weeks. Taken together, the
promising preclinical evidence of PDGF therapy in periodontal, peri-implant, and bone
augmentation indications established the foundation for therapeutic evaluation of PDGF in
clinical applications
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C.2. Clinical Studies Using PDGF for Periodontal and Peri-implant Regeneration
The use of rhPDGF for dental implant site development (i.e. sinus augmentation)34,
horizontal bone augmentation35 and ridge preservation36 has been investigated in human
studies, however the primary focus of clinical studies using this agent has been in
periodontal and peri-implant regenerative indications.48
An early human clinical trial to evaluate the effect of rhPDGF/IGF treatment applied to
osseous periodontal defects was reported by Howell and co-workers.37 The experimental
sites received direct application of the GFs contained in a methylcellulose matrix to improve
retention. A statistically significant increase in alveolar bone formation was seen in the
growth factor treated sites at nine months post-operatively, as compared to untreated control
sites. Average bone height for the PDGF/IGF group was 2.08 mm and 43.2 % osseous
defect fill was achieved, as compared to 0.75 mm new bone height and 18.5% fill in the
control sites.
Based on the principles of tissue engineering, the use of a growth factor enhanced matrix for
periodontal regeneration consisting of rhPDGF-BB in combination with an osteoconductive
scaffold (i.e., autograft, allograft, xenograft, or a synthetic matrix, such as beta-TCP) was
proposed.38 The rationale underlying this approach is that PDGF stimulates angiogenesis,
promotes cell migration into the bone defect from the surrounding tissue margins, and
upregulates cell proliferation.39 The matrix, in addition to its role as a growth factor delivery
vehicle, provides mechanical support for migrating cells and contributes to the formation of
new bone, cementum and/or periodontal ligament.
Early human clinical studies utilized rhPDGF-BB combined with bone allograft. In one of
these studies the effectiveness of rhPDGF-BB treatment for extensive interproximal
intrabony defects and Class II furcation lesions associated with advanced periodontitis was
evaluated.40, 41 Surgical procedures involved full-thickness flap reflection, thorough
debridement of the defect site, and subsequent filling of the defect with demineralized
freeze-dried bone allograft (DFDBA) presoaked in a solution containing rhPDGF-BB at
three different concentrations (0.5, 1.0 or 5.0 mg/mL). Control defect sites were filled with
commercially available anorganic bovine bone in collagen (Figure 3). Clinical probing
depths and attachment levels were assessed at periodic intervals up to nine months post-
operatively, at which time the treated teeth were removed en bloc for histological analysis.
The study results indicated that substantial improvements in vertical and horizontal probing
depths over baseline levels were achieved for all sites treated with rhPDGF-BB. Histological
evaluation revealed robust periodontal regeneration in the rhPDGF-BB sites, including new
bone, cementum and periodontal ligament formation (Figure 3). Statistical analysis indicated
that rhPDGF-BB combined with allograft bone produced robust regeneration and improved
gingival attachment in interproximal bone defects and Class II furcation defects, compared
to baseline. Comparisons among doses indicated that there were no adverse reactions, even
at the highest dose, indicating that rhPDGF-BB was well tolerated in periodontal defect
sites. Important to note is that this was the first study reporting clear histological evidence of
periodontal regeneration for human Class II furcation defects using this approach.41 The
regenerative effects of rhPDGF in combination with mineralized freeze dried bone allograft
have been further documented clinically in a case study reported by Nevins and co-workers.
42 Two patients presenting with extremely severe bone loss (teeth with a poor to hopeless
prognosis) and requiring surgical bone grafting were treated with rhPDGF-BB enhanced
mineralized allograft. Defect sites were treated with freeze-dried bone allograft saturated
with rhPDGF-BB at a concentration of 0.3 (Case 1) or 1.0 mg/mL (Case 2). The growth
factor-enhanced matrix was packed into the defect and an absorbable barrier membrane was
placed over the defect prior to soft tissue closure. Patients were followed for six months, at
which time a surgical re-entry procedure was performed to evaluate the healing response
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within these previously severe defects. Both patients in this limited study exhibited excellent
soft tissue healing. At six months, probing depths for both patients were 3 mm and gingival
recession was 0 mm and 3 mm for Case 1 and Case 2, respectively. The gains in clinical
attachment level relative to baseline were 7 mm and 2 mm for Case 1 and Case 2,
respectively. No adverse effects associated with either rhPDGF-BB dose were observed.
Radiographic findings of excellent bone fill at six months for both patients were confirmed
upon surgical reentry of the treated sites. These results demonstrate that rhPDGF-BB
combined with freeze-dried bone allograft provides an effective treatment for severe
periodontal bone loss.
An alternative to an allograft is the use of a completely synthetic growth factor enhanced
matrix system. rhPDGF-BB has been combined with β−tricalcium phosphate (β-TCP), a
well-established resorbable ceramic biomaterial commonly used in oral reconstructive
surgery. The results of a large, multicenter clinical trial evaluating the effectiveness of
rhPDGF-BB combined with a porous β-TCP matrix have been recently reported.43 This
study included 180 participants with one interproximal periodontal defect 4 mm or deeper
after debridement. Other noteworthy inclusion criteria included a baseline probing depth of
7 mm or greater, sufficient keratinized gingiva to allow complete coverage of the defect,
radiographic defect base at least 3 mm coronal to the apex of the tooth, and no evidence of
localized aggressive periodontitis. Grade I and Grade II furcation defects were acceptable
for inclusion in the study. Smokers who consumed up to one pack per day were also
included in the study. Three treatment groups were evaluated: 1) β-TCP plus 0.3 mg/ml
rhPDGF-BB (Group I), 2) β-TCP plus 1.0 mg/ml rhPDGF-BB (Group II), and 3) β-TCP
plus buffer alone (Group III). Defects were classified as 1-wall, 2-wall or 3-wall /
circumferential, indicating the extent of involvement and severity. At the time of surgery, β-
TCP granules were saturated with rhPDGF-BB before the graft was placed in the defect site.
Patients were followed for a period of six months and outcome measures included
evaluation of soft tissue changes and assessment of bone growth. Safety was monitored
throughout the trial by assessing the frequency and severity of clinical and/or radiographic
adverse events.
Excellent healing was observed for all defects treated with rhPDGF-BB. The study results
demonstrated that there was a significantly greater clinical attachment level gain at three
months for the 0.3 mg/ml rhPDGF-BB (Group I), as compared to the β-TCP controls (Group
III), indicating an early benefit of rhPDGF-BB treatment. At six months, the clinical
attachment level gain for the lower rhPDGF-BB concentration group continued to be greater
than the control group, although statistical significance was not achieved. Additionally,
rhPDGF-BB treatment resulted in significantly less gingival recession at three months, as
compared to the untreated control group. This difference was no longer apparent at six
months, however, as the control group exhibited a slight gain in gingival height over time.
Increasing the rhPDGF-BB concentration appeared to reduce the effectiveness of the growth
factor-enhanced matrix. No statistically significant differences were observed in clinical
attachment level or gingival recession for the higher rhPDGF-BB concentration (Group II),
as compared to the β-TCP controls. Radiographic assessment revealed that bone fill was
significantly increased at six months for the lower rhPDGF-BB concentration, as compared
to both the higher rhPDGF-BB concentration and the control group (Figure 4). A subgroup
analysis further indicated that rhPDGF-BB treatment improved bone fill in smokers and for
all defect types (1, 2, 3 wall and circumferential) (Figure 5). Similarly, linear bone growth
was also significantly greater for Group I, as compared to Groups II and III. No significant
differences were observed in the number or severity of adverse events among the three
groups, indicating that both rhPDGF-BB and the β-TCP matrix were safe and adequately
tolerated in the defect site. The results of this study demonstrate that the use of rhPDGF-BB
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in combination with a synthetic β-TCP matrix accelerates the rate of bone regeneration and
improves bone fill and clinical attachment level in surgically treated periodontal defects.
These positive outcomes were maintained over time as reported in a patient case series.44
Four patients, selected from centers participating in the original pivotal clinical trial,
exhibited significantly enhanced results for sites treated with 0.3 mg/ml rhPDGF and β-TCP
in a long-term (24 month) evaluation. These results remained significantly improved over
results observed for the β-TCP control group (Figure 6).
Placing these clinical results in perspective, the use of 0.3 mg/ml rhPDGF and β-TCP for the
treatment of periodontal defects compares very favorably to existing FDA approved
treatments in terms of clinical attachment level gain and bone fill. This therapeutic approach
significantly improved both clinical soft tissue and radiographic measures, as compared to
the control group. The superior results for the lower dose suggest that there may be an
optimum level of rhPDGF required to effectively stimulate a cellular response that leads to
regeneration in periodontal defects. This observation emphasizes the need for rigorous
clinical studies of new growth factor therapies, including systematic examination of dose
effects.
Though delivery of rhPDGF has shown clinical efficacy in the treatment of intrabony
defects, it has also been examined for the treatment of soft tissue recession defects. In a case
series study conducted by McGuire and colleagues,45 seven subjects presenting contralateral
> 3 mm-deep recession defects (Miller Class I and II) receive two different types of
treatment in a split-mouth design. Test therapy consisted of a combination of rhPDGF/β-
TCP and a collagen membrane. The control treatment applied was the gold standard for root
coverage: the subepithelial connective tissue graft (CTG). Healing was evaluated at 8, 16,
and 24 weeks following the interventions. Primary outcome measure was recession depth.
Results indicated a favorable tissue response to the test therapy, with comparable clinical
outcomes to CTG in terms of root coverage and keratinized tissue width.
In a later publication, McGuire and co-workers reported histologic and microtomographic
findings following analysis of human en-block samples of teeth that received either CTG or
a combination of rhPDGF/β-TCP and a wound healing dressing.46 Two patients requiring
the extraction of a total of six premolars as part of orthodontic therapy were included in the
study. Gingival recession defects were surgically created in the buccal aspect of these teeth
and when necessary, alveolar bone was resected to position the crest at 2–3 mm from the
newly created gingival margin. In all teeth reference notches were created at the level of the
new gingival margin and at the bone crest. Defects were left untouched for two months prior
to the performance root coverage procedures and a total of two CTG and four rhPDGF/β-
TCP procedures were performed. After a nine-month healing period biopsies were obtained
and defects were grafted. Clinically, 100% root coverage was achieved in all surgical sites.
However, histologic and microtomographic results were distinct for both treatment groups.
While, none of the CTG-treated sites showed signs of periodontal regeneration (healing was
characterized by a long juctional epithelium and parallel connective tissue fibers, with
minimal new cementum formation), all four rhPDGF/β-TCP-treated sites exhibited
periodontal regeneration. This was evidenced by the presence of periodontal ligament
interposed between newly formed cementum and alveolar bone, situated above the reference
apical notch.
Preliminary evidence provided by these studies suggests the need for further investigation
consisting of the conduction of controlled clinical trials of greater magnitude, designed to
evaluate the application of GF-based therapy as a more favorable option than CTG for
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patients requiring gingival recession coverage, since the need for a second surgical site
could be eliminated.
EXPERT OPINION
A combination of rhPDGF with a tissue specific scaffold, such as those comprised of
allograft materials or synthetic bioresorbable ceramics, has the potential to fulfill the clinical
need for a biomaterial that predictably leads to periodontal or peri-implant regeneration. The
results of a large, multi-center clinical trial aimed at evaluating the clinical safety and
effectiveness of rhPDGF-BB incorporated in a β-TCP matrix demonstrate that this product
is safe for long-term use. This treatment approach is supported by extensive and rigorous in
vitro, preclinical and clinical studies, which provide strong evidence for the mechanism of
action of PDGF in periodontal and peri-implant healing and regeneration. Growth factor-
enhanced matrices provide clinicians with a new, highly effective treatment option for
challenging periodontal lesions, which are difficult to treat using conventional methods.
Promising clinical results for rhPDGF in combination with osteoconductive matrices in a
diverse array of periodontal and periimplant sites suggest that growth factor-enhanced
matrices incorporating rhPDGF have the potential to become routine, a standard of care
treatment modality.
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FIGURE 1.
Four basic elements are required for periodontal repair and regeneration: adequate blood
supply and wound stability, a source of bone and ligament forming cells, a supporting
scaffold or matrix, and growth factors to regulate cell migration, proliferation and synthesis
and angiogenesis for revascularization of the site.
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FIGURE 2.
rhPDGF is associated with increased bone formation in a canine alveolar ridge augmentation
model. Baseline surgically created defect (A, B), was treated using guided bone regeneration
(GBR) with equine bone block infused with rhPDGF-BB (C). Excellent bone formation is
seen at four months in the treated site (D). Figures E and F show the histologic outcomes,
with special emphasis on the remarkable bone-to-implant contact achieved. Reprinted with
permission from Quintessence Publishing Co., Inc.47
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FIGURE 3.
A growth factor-enhanced matrix (GEM) can consist of allograft bone saturated with
rhPDGF-BB. The matrix is saturated with pure, recombinant growth factor solution prior to
being packed into the defect site. This case illustrates the use of rhPDGF and allograft to
treat a class II furcation with a mesial wrap-around defect. A) debrided defect; B) grafted
site; C and D) histology showing periodontal regeneration coronal to a reference notch
placed at the base of calculus prior to treatment (NC – New cementum; NB – New Bone;
PDL – Periodontal ligament; TR – Tooth Roots). Reproduced with permission.37
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FIGURE 4.
rhPDGF-BB in combination with β-TCP significantly improved %BF of all bone defects
compared to β-TCP plus buffer.43
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FIGURE 5.
rhPDGF-BB treatment resulted in significantly improved bone fill in 1-, 2-, and 3-wall
defects (p<0.001); there was no significant difference in bone fill between 1- and 2-wall
defects compared to 3-wall and circumferential defects (p=0.40 in the 0.3 mg/ml group).43
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FIGURE 6.
Representative case from pivotal clinical trial treated with 0.3 mg/ml rhPDGF. A, B and C)
Baseline; D) 6 months post-surgically; E) 18 months post-surgically. Note progressive
increase in radiopacity and trabecular bone pattern in the area of the original defect.
Reprinted with permission.44
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